CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00907101
NCT00907101Phase 4Completed
CompareCT.gov

Evaluation of the Effectiveness of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) in Reducing Antibiotic Sensitive and Resistant Strains of P Acnes

Galderma R&D·interventional·Posted May 22, 2009·Updated Aug 1, 2022

In Brief

A Phase 4 clinical trial evaluating Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel) for P Acnes Colonization. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effectiveness of Epiduo® Gel in reducing antibiotic sensitive and resistant strains of P acnes in vivo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsP Acnes Colonization
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 22, 2009
Enrollment StartJun 1, 2009
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.1 years ago

Interventions

Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)drug

Apply once daily